Important Safety Information on CRYSVITA (burosumab) and the Risk of Severe Hypercalcemia in Patients with Tertiary Hyperparathyroidism
Issued August 25, 2025
Issue
CRYSVITA (burosumab) may increase the risk of severe hypercalcemia in patients with underlying tertiary hyperparathyroidism and other risk factors, such as prolonged immobilization, dehydration, hypervitaminosis D, or renal impairment.
Hazard description
New safety information - Product safety
Product
Product name
CRYSVITA (burosumab)
Reference
ID
RA-77973
Get notified of similar recallsEnter your email to receive alerts when new recalls are issued by the same agency.
Subscribed. You'll get an email when new recalls are issued.
RecallTracker